Drug Profile


Alternative Names: ABT-333; Exviera; Viekira Pak (dasabuvir combination therapy); VIEKIRA XR

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antivirals; Naphthalenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 02 Dec 2016 The EMA’s Pharmacovigilance Risk Assessment Committee issues a warning about the risk of hepatitis B-reactivation with direct-acting antiviral drugs, including Dasabuvir
  • 01 Dec 2016 AbbVie completes the phase III RUBY-II trial for Hepatitis C in Australia, New Zealand, Spain and the UK (NCT02487199)
  • 01 Dec 2016 AbbVie completes the GARNET trial in Hepatitis C (Combination therapy, Treatment-naive) in Australia, Canada, France, Germany, Italy, Spain, United Kingdom and Israel (NCT02582632)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top